The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies.
M. Pia Morelli
No relevant relationships to disclose
Michael J. Overman
Research Funding - Amgen
Arvind Dasari
No relevant relationships to disclose
Syed Mohammad Ali Kazmi
No relevant relationships to disclose
Eduardo Vilar Sanchez
No relevant relationships to disclose
Cathy Eng
No relevant relationships to disclose
Bryan K. Kee
No relevant relationships to disclose
Laurel Deaton
No relevant relationships to disclose
Chris R. Garrett
No relevant relationships to disclose
Frank Diehl
Employment or Leadership Position - Inostics
Stock Ownership - Inostics
Honoraria - Inostics
Philipp Angenendt
Employment or Leadership Position - Inostics
Stock Ownership - Inostics
Scott Kopetz
No relevant relationships to disclose